A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Prior treatment

• Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening
• Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation
• Use of insulin therapy for T2DM within 3 months prior to screening

Other illness

• Obesity primarily caused by other endocrine disorders

Lab values

• Significant hepatobiliary disease and/or any of the following results at Screening:
  • ALT ≥ 3.0 X ULN
  • AST ≥ 3.0 X ULN
  • TBL \> 1.5 X ULN (except for cases of known Gilbert's Syndrome)

• Males \& females (inclusive of all gender identities) age ≥18 years
• BMI ≥27 kg/m2
• Diagnosed with T2DM ≥90 days prior to Screening
• HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling)
• Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation
• History of at least one self-reported unsuccessful attempt to lose body weight in lifetime